Sera Prognostics Says PRIME Trial Shows PreTRM-Guided Care Cuts Preterm Births Before 32 Weeks by over 50%

Sera Prognostics Announces CFO Transition and Succession Plan

Sera Prognostics Names Scott Gleason CFO Effective Aug. 31

Sera Prognostics, - Austin Aerts to Transition from CFO to Advisory Role

Vivos Therapeutics Q2 Revenue Rises 35% on Service Growth

Analyst Reiterates Buy on Sera Prognostics, Citing Expanding Payer Coverage and Large Long‑Term Market Opportunity

Sera Prognostics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Sera Prognostics Q2 Revenue Rises on Expanded Partnerships and Medicaid Coverage

Sera Prognostics Q2 EPS USD -0.18

Sera Prognostics Q2 FY26 Net Loss Widens to $9.14 Million; Revenue Rises 76.47% to $30,000

Sera Prognostics Q2 EPS $(0.18) Misses $(0.15) Estimate, Sales $30.000K Miss $57.500K Estimate

Press Release: SERA Prognostics Reports Second Quarter 2026 Financial Results

Sera Prognostics, Inc. Expected to Post a Loss of 15 Cents a Share - Earnings Preview

Sera Prognostics Schedules Conference Call, Webcast for Quarterly Results Update

Sera Prognostics management to meet virtually with Craig-Hallum

Sera Prognostics’ PreTRM Test shows efficacy guiding first-time pregnancy care

Sera Prognostics Announces New PRIME Subgroup Analysis Publication on Pretrm Test-guided Care

Sera Prognostics Director Mark Christopher Capone Files Initial Beneficial Ownership Statement

Sera Prognostics Adds Veteran Executive to Board